A rapid review and a systematic review both aim to answer a defined research or policy question by identifying, appraising, and synthesizing existing evidence — but they are not the same product, and using the terms interchangeably misleads readers about how rigorously the underlying literature was searched and screened. A rapid review is best understood as a form of evidence synthesis that deliberately streamlines or omits specific systematic review methods to produce a usable answer in a shorter timeframe, typically because a decision (a policy choice, a clinical guideline update, an urgent funding or regulatory question) cannot wait the many months a full systematic review requires. This guide covers where the two diverge methodologically, why researchers and evidence-synthesis teams choose one over the other, and what reporting conventions currently apply to each — including the real, current state of rapid-review-specific reporting guidance, which is still under development.
What counts as a rapid review
The Cochrane Rapid Reviews Methods Group (RRMG) defines a rapid review as a form of knowledge synthesis that accelerates the process of conducting a traditional systematic review by streamlining or omitting specific methods, in order to produce evidence for stakeholders in a resource-efficient manner. The RRMG published interim methods guidance in 2020 (Garritty et al.) based on a scoping review of the methodological literature and a structured survey of Cochrane entities, and issued updated recommendations in 2024 refining that guidance based on further evaluation and expert input. Rapid reviews sit alongside other abbreviated or purpose-specific review types — scoping reviews, critical reviews, umbrella reviews — in typologies such as Grant and Booth’s widely cited 2009 classification of 14 review types sharing a common Search, AppraisaL, Synthesis, Analysis (SALSA) framework. What distinguishes a rapid review within that family is that it still targets the same kind of question a systematic review would (commonly an effectiveness or intervention question) but compresses the process rather than changing the question type, which is the key difference from a scoping review (see CASRAI’s comparison of literature, systematic, and scoping reviews for how scoping reviews differ in aim rather than just speed).
Where the methodology actually diverges
The differences between a rapid review and a full systematic review are not vague or a matter of general “less effort” — they map onto specific, identifiable stages of the review process. A systematic review conducted per the Cochrane Handbook for Systematic Reviews of Interventions and reported per PRISMA 2020 is built around exhaustiveness: the goal is to minimize the risk of missing relevant evidence. A rapid review accepts a higher, but explicitly acknowledged, risk of missing some evidence in exchange for speed. The Cochrane RRMG guidance and related methods literature identify streamlining choices concentrated in a few recurring places:
- Search strategy and database scope. A systematic review typically searches multiple bibliographic databases (commonly including a combination such as MEDLINE, Embase, and CENTRAL, plus trial registries and grey literature) with no date or language restriction unless justified. A rapid review commonly limits the search to fewer databases (sometimes a single major database), applies date limits, restricts to English-language studies, or forgoes hand-searching and grey-literature searching — trade-offs that the review must disclose, not just apply silently.
- Study selection and screening. Systematic reviews generally require independent dual-reviewer screening of titles/abstracts and full texts, with a documented process for resolving disagreement. Rapid reviews frequently use single-reviewer screening, sometimes with a second reviewer checking only a sample or only the excluded set, to cut screening time substantially.
- Data extraction and critical appraisal. Dual, independent data extraction and risk-of-bias assessment are standard in a systematic review. Rapid reviews often move to single-reviewer extraction with spot-checking by a second reviewer, or use abbreviated/rapid critical-appraisal tools rather than the full instrument a systematic review would apply.
- Synthesis. Systematic reviews frequently proceed to formal meta-analysis where data permit. Rapid reviews more often present a narrative or tabular synthesis, since the abbreviated search and appraisal process makes a pooled effect estimate harder to defend with confidence.
- Timeline. This is the practical driver behind all of the above. Systematic reviews commonly take upward of a year from protocol to publication; rapid reviews are typically commissioned and delivered on the order of weeks to a few months, which is the entire reason the other shortcuts exist.
Every one of these is a spectrum, not a fixed checklist — “rapid review” describes a family of streamlined approaches rather than one standardized protocol, which is itself one of the methodological challenges the field is actively working to address (see reporting conventions, below).
Why teams choose a rapid review over a full systematic review
The decision is rarely about preference — it is a response to a genuine time constraint on the decision the evidence is meant to inform. Common drivers include:
- Policy or public-health urgency. The WHO’s 2017 practical guide, Rapid Reviews to Strengthen Health Policy and Systems (Tricco, Langlois, and Straus), was developed specifically because health policymakers frequently need an evidence synthesis on a timeline a traditional systematic review cannot meet, and needed methods guidance on when a rapid review is an appropriate substitute rather than an ad hoc shortcut.
- Guideline development and update cycles. Clinical and public-health guideline panels sometimes commission a rapid review to inform an interim recommendation, or to decide whether a full systematic review update is warranted at all.
- Resource constraints. A rapid review requires less reviewer time and often a smaller team, which matters for organizations without the sustained capacity a multi-reviewer systematic review team requires.
- Emerging or fast-moving evidence bases. Where the literature on a question is small or rapidly changing, some methods researchers argue a highly exhaustive search is a poor use of time relative to the marginal evidence it would add — though this argument depends heavily on the topic and should not be assumed.
The tradeoff a rapid review makes is not free: a narrower search and abbreviated appraisal genuinely raise the risk of missing relevant studies or overlooking methodological flaws in included studies. The appropriate response, per Cochrane RRMG and WHO guidance alike, is not to avoid rapid reviews but to be explicit — in the protocol and in the published report — about exactly which shortcuts were taken and why, so a reader can weigh the evidence accordingly.
Reporting conventions: what exists today, and what is still under development
This is the area where researchers most often overstate what’s actually standardized. For a full systematic review, the reporting landscape is mature: PRISMA 2020 is the dominant reporting checklist — most recently updated as PRISMA 2026, which adds an AI-assisted-screening disclosure item and a parallel living-review reporting checklist — PRISMA-P governs protocol reporting, and the PRISMA flow diagram is the near-universal way of documenting the search-to-inclusion pipeline (CASRAI has a full systematic review protocol template aligned to PRISMA-P). Scoping reviews have their own extension, PRISMA-ScR.
There is currently no equivalent, published PRISMA extension specific to rapid reviews. A protocol for developing PRISMA extensions covering rapid reviews (alongside updates for network meta-analysis and scoping reviews) was registered with the EQUATOR Network and published as a scoping-review protocol in 2025; as of this writing that work defines candidate reporting items — such as explicitly justifying and distinguishing which systematic review methods were abbreviated or omitted, disclosing knowledge-user involvement, and documenting peer review of the rapid review itself — but has not yet produced a finalized, published checklist. Authors and editors should not cite a “PRISMA-RR” as an existing, adoptable standard; it is, at most, in development.
In the absence of a dedicated PRISMA extension, the working reporting conventions for rapid reviews come from two sources:
- The Cochrane RRMG’s methods guidance (2020 interim guidance, updated 2024), which functions as the closest thing to a methodological standard currently in active use, and explicitly recommends that authors report which shortcuts were taken relative to a full systematic review, and why, rather than presenting a rapid review’s methods section as if it were a standard systematic review with fewer words.
- The WHO’s practical guide to rapid reviews for health policy and systems, which frames reporting requirements around transparency for the policymaker audience the review is meant to serve.
Until a dedicated PRISMA extension is finalized, the most defensible practice — and the one implicit in both the Cochrane and WHO guidance — is for a rapid review to: (1) explicitly label itself as a rapid review, not a systematic review, in the title and abstract; (2) report the same core PRISMA 2020 items where they apply, since most of the checklist (objectives, eligibility criteria, results reporting, limitations) is not specific to search exhaustiveness; and (3) add an explicit methods subsection stating which systematic review methods were streamlined or omitted (databases searched, single- vs dual-reviewer screening, appraisal tool used) and the rationale, so a reader can assess the evidence base’s reliability without needing to infer it. CASRAI’s guide on peer-reviewing a systematic review or meta-analysis covers the reviewer-side checks this transparency is meant to support.
What a rapid review is not a substitute for
A rapid review is a legitimate, purpose-built method — not a lesser or “quick and dirty” version of a systematic review that happens to have been rushed. Using it appropriately means matching the method to the decision: a rapid review is well suited to an urgent policy or guideline question where some residual uncertainty about search completeness is an acceptable tradeoff for timeliness, and poorly suited to a question (a definitive treatment-effectiveness determination, a regulatory submission, a Cochrane-standard intervention review) where the entire value of the output depends on comprehensive, low-bias evidence identification. Reviewers, editors, and funders assessing a rapid review should treat the abbreviated methodology as a disclosed limitation to weigh, not a defect to penalize outright, provided the streamlining was reported transparently.
Frequently asked questions
Is a rapid review peer reviewed the same way a systematic review is?
Journals generally apply the same peer review process to both, but reviewers should specifically check that a rapid review discloses its methodological shortcuts (search scope, screening approach) rather than presenting itself as methodologically equivalent to a full systematic review.
Can a rapid review be upgraded into a full systematic review later?
Yes — a rapid review is sometimes explicitly framed as a first pass that a team later expands into a full systematic review if the initial evidence signals warrant it, particularly in guideline-development contexts where an interim recommendation is needed before the complete review is finished.
Does Cochrane publish rapid reviews itself?
The Cochrane Rapid Reviews Methods Group develops and maintains methods guidance for rapid reviews conducted both within Cochrane and by outside teams; it does not mean every rapid review is a Cochrane-branded publication in the way a standard Cochrane systematic review is.
Is “PRISMA-RR” a real, citable standard?
Not yet, as of this writing. Development work — registered with the EQUATOR Network and published as a protocol in 2025 — is underway to build a PRISMA extension for rapid reviews, but no finalized checklist has been published. Cite the Cochrane RRMG guidance or the WHO practical guide instead of an unpublished “PRISMA-RR.”
This guide reflects the state of rapid-review methodology and reporting guidance as of 2026; because a dedicated PRISMA extension for rapid reviews is actively in development, check the EQUATOR Network for the current status before assuming the landscape described here is still current.
